<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11308269</article-id><article-id pub-id-type="pmc">2363902</article-id><article-id pub-id-type="pii">6691747</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1747</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heatherington</surname><given-names>A C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schuller</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mercer</surname><given-names>A J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><aff id="aff1">Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, 91320&#x02013;1799, USA</aff><aff id="aff2">Krankenanstalt Rudolstiftung, Medizinische Abteilung &#x02013; Onkologie, Juchgasse 25, Vienna 1030, Austria</aff><aff id="aff3">Amgen Ltd, Milton Road, Cambridge CB4 OWD, UK</aff></contrib-group><pub-date pub-type="ppub"><month>4</month><year>2001</year></pub-date><volume>84</volume><issue>Suppl 1</issue><fpage>11</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &#x000a9; 2001 Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Anaemia is a common occurrence in patients with cancer, and currently can be treated in several ways. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa) was created using site-directed mutagenesis to have 8 more sialic acid side chains than recombinant human erythropoietin (rHuEPO). The additional sialic acid content has resulted in an approximately 3-fold greater half-life relative to rHuEPO in patients with chronic renal failure. This study evaluates the pharmacokinetic profile of NESP in patients receiving multiple cycles of chemotherapy. Anaemic patients (haemoglobin &#x02264; 11.0&#x02008;g&#x02008;dl<sup>&#x02212;1</sup>) who had non-myeloid malignancies received NESP weekly (2.25&#x02008;mcg&#x02008;kg<sup>&#x02212;1</sup>&#x02008;wk<sup>&#x02212;1</sup>) under the supervision of a physician, starting on day 1 of chemotherapy for 3 chemotherapy cycles given at 3-week intervals. Blood samples were collected during chemotherapy cycles 1 and 3 for pharmacokinetic analysis. All patients were followed for 4 weeks after treatment. NESP was well tolerated by all patients. After a single dose during chemotherapy cycle 1, pharmacokinetic parameters (mean (SD), <italic>n</italic>) for the first 15 patients were: T <sub>max</sub> 86.1 (22.8)&#x02008;h (<italic>n</italic> = 14); C <sub>max</sub> 9.0 (5.1)&#x02008;ng&#x02008;ml<sup>&#x02212;1</sup>(<italic>n</italic> = 14); t <sub>1/2,z</sub> 32.6 (11.8)&#x02008;h (<italic>n</italic> = 7); CL/F 3.7 (1.0)&#x02008;ml&#x02008;h<sup>&#x02212;1</sup>&#x02008;kg<sup>&#x02212;1</sup>(<italic>n</italic> = 7). The subjects for whom all parameters could be calculated may represent a sub-group of the entire population. Similar results were obtained in cycle 3. In addition, haemoglobin response data suggests that, in this patient population, dosing less frequently than the 3 times weekly doses used for rHuEPO may be possible while improving anaemia. &#x000a9; 2001 Cance Cancer Research Campaign</p></abstract><kwd-group><kwd>cancer</kwd><kwd>chemotherapy</kwd><kwd>clinical study</kwd><kwd>darbepoetin alfa</kwd><kwd>pharmacokinetics</kwd></kwd-group></article-meta></front></article>
